↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration

Overview of attention for article published in Therapeutics and Clinical Risk Management, July 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
34 Mendeley
Title
Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
Published in
Therapeutics and Clinical Risk Management, July 2012
DOI 10.2147/tcrm.s32801
Pubmed ID
Authors

Fei Han, Chen, Fei Han

Abstract

Wet age-related macular degeneration (AMD) causes severe vision loss due to the development of choroidal neovascularization (CNV). The critical role of vascular endothelial growth factor in the pathogenesis of CNV is well understood. Ranibizumab plays an inhibitory role with CNV and reduces vascular permeability by binding to vascular endothelial growth factor. Intravitreal ranibizumab reduces the risk of visual acuity (VA) loss and increases the chance of VA gain compared with no treatment or photodynamic therapy for CNV in AMD. Some high-quality research has shown that the optimal timing for ranibizumab treating wet AMD is the first 3 months. It is recommended that ranibizumab is intravitreally injected monthly in the initiation for at least 3 months. Subsequent managing of regimens should be made dependent on the VA change, fundus examination, and image of optical coherence topography. An individualized strategy or combined method with photodynamic therapy is beneficial to the active lesion in the consecutive treatment of ranibizumab for CNV, and may be a good choice in order to decrease injection times. Regarding the safety profile, ranibizumab has been well tolerated in clinical trials. The principal ocular adverse event detected in clinical trials is a low frequency of ocular inflammation. Key serious ocular adverse events occurred in <5% of ranibizumab-treated patients in large-scale clinical trials. It appears unlikely that treatment with ranibizumab increases the risk of vascular events significantly. Less frequent injections on an as-needed schedule, based on monthly monitoring may have the most optimal risk:benefit ratio.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 21%
Other 6 18%
Researcher 6 18%
Student > Bachelor 6 18%
Student > Ph. D. Student 2 6%
Other 2 6%
Unknown 5 15%
Readers by discipline Count As %
Medicine and Dentistry 12 35%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Economics, Econometrics and Finance 3 9%
Agricultural and Biological Sciences 2 6%
Nursing and Health Professions 2 6%
Other 5 15%
Unknown 7 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2012.
All research outputs
#4,204,254
of 5,037,615 outputs
Outputs from Therapeutics and Clinical Risk Management
#439
of 487 outputs
Outputs of similar age
#66,531
of 80,791 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#7
of 10 outputs
Altmetric has tracked 5,037,615 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 487 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 80,791 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.